Saturday 17 October 2026
Export MD’s income statement to Excel — free account
Pediatrix Medical Group, Inc.
MD Healthcare Medical Care Facilities
Pediatrix Medical Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 4.92% from fiscal 2024. In the quarter to June 2026, revenue grew 4.04%, EPS grew 6.52%, free cash flow fell 6.56% and total debt fell 3.84%, each against the same quarter a year earlier.
27.38
0.38
−1.37%
Follow MD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
12.12 | 10.38 | 11.03 | 8.82 |
+8 more quarters Free account |
P/S ratio |
1.03 | 0.90 | 0.94 | 0.74 | |
P/FCF ratio |
8.80 | 7.29 | 7.12 | 5.18 | |
P/Operating CF |
16.06 | (13.32) | 15.76 | 10.32 | |
P/B ratio |
2.28 | 1.97 | 2.08 | 1.59 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.12 | 1.03 | 0.99 | 0.81 | |
EV/EBITDA |
9.17 | 8.24 | 8.19 | 6.97 | |
EV/Operating CF |
8.88 | 7.70 | 6.99 | 5.37 | |
EV/FCF |
9.59 | 8.39 | 7.51 | 5.69 | |
Quick Ratio |
1.28 | 1.28 | 1.62 | 1.78 | |
Current Ratio |
1.32 | 1.33 | 1.66 | 1.83 | |
Net Debt/EBITDA |
2.87 | 5.47 | 1.79 | 1.89 | |
Debt/Assets |
27.42% | 28.54% | 26.59% | 27.39% | |
Debt/Equity |
0.66 | 0.67 | 0.69 | 0.68 | |
Asset Turnover |
0.92 | 0.95 | 0.87 | 0.90 | |
Operating CF/Net income |
3.15 | (4.39) | 3.39 | 1.91 | |
Capex/Depreciation |
(0.24) | (1.00) | (0.90) | (0.92) | |
Interest Coverage |
6.97 | 5.04 | 5.58 | 7.61 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
12.57% | 12.66% | 13.30% | 12.33% | |
Intangible Assets out of Total Assets |
0.60 | 0.62 | 0.57 | 0.58 | |
Share Based Compensation of Revenue |
1.04% | 0.98% | 1.08% | 1.04% | |
Graham Net Nets |
(0.29) | (0.35) | (0.34) | (0.42) | |
Graham Number |
22.84 | 22.44 | 21.20 | 21.21 | |
Earnings Yield |
8.25% | 9.63% | 9.07% | 11.34% | |
Free Cash Flow Yield |
11.36% | 13.72% | 14.05% | 19.29% | |
Revenue per Share |
6.14 | 5.89 | 5.87 | 5.83 | |
Operating CF per Share |
1.58 | (1.61) | 1.36 | 1.62 | |
Capex per Share |
(0.02) | (0.08) | (0.06) | (0.06) | |
Free Cash Flow per Share |
1.56 | (1.68) | 1.29 | 1.56 | |
Cash per Share |
5.09 | 4.07 | 5.94 | 5.47 | |
Shareholders Equity per Share |
11.09 | 10.86 | 10.30 | 10.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.09 | 10.86 | 10.30 | 10.53 | |
Free Cash Flow |
123.94 | (136.09) | 108.82 | 131.95 | |
Working Capital |
158.56 | 144.40 | 304.60 | 324.65 | |
Capital Expenditures |
(1.38) | (6.25) | (5.29) | (5.34) | |
Net Current Asset Value |
(589.22) | (604.68) | (617.33) | (591.54) | |
EV/EBIT |
10.18 | 9.12 | 9.08 | 7.81 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
9.34 | 7.92 | 8.61 | 7.11 | |
| Other line items | |||||
Average Receivables |
242.81 | 244.90 | 257.46 | 261.52 | |
Average Payables |
302.60 | 235.55 | 409.11 | 342.86 | |
Average Assets |
2,116.22 | 2,031.89 | 2,199.70 | 2,138.14 | |
Average Common Equity |
857.37 | 833.88 | 815.40 | 811.58 |
Columns are period end dates